Skip to main content

Key Product Details

Species Reactivity

Human, Rat

Applications

Western Blot

Label

PE (Excitation = 488 nm, Emission = 575 nm)

Antibody Source

Monoclonal Mouse IgG2B Clone # OTI5H6

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

Human recombinant protein fragment corresponding to amino acids 202-426 of human FCRLB(NP_001002901) produced in E.coli.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2B

Applications for FCRLB/FCRY Antibody (OTI5H6) [PE]

Application
Recommended Usage

Western Blot

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Formulation

PBS

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: FCRLB/FCRY

FCRLB, also known as FcRY, is a 57 kDa protein that is structurally related to receptors for immunoglobulin Fc regions. It is an intracellular molecule that contains three Ig-like domains and a mucin-like domain. FCRLB is expressed in placenta and by several B cell populations.

Long Name

Fc Receptor-like B

Alternate Names

FcRL2, FCRLM2, FCRLY, FCRY, FREB-2

Gene Symbol

FCRLB

Additional FCRLB/FCRY Products

Product Documents for FCRLB/FCRY Antibody (OTI5H6) [PE]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for FCRLB/FCRY Antibody (OTI5H6) [PE]

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...